|
|
TCRT-PGEN Fundamental & Technical Discussion Board
|
|
||
Checklist1–Autologous PBL T cells modified by SB to express TCR’s THAT RECOGNIZE MULTIPLE NEOANTIGENS grown to levels in prior NCI trials infusing TIL’s for solid tumor. PBL’s as per Rosenberg with clear specific enhanced attributes vs TILS. 2–Drew Deniger votes with his feet toleave his prominent NCI position and join Ziop as the momentously significant trial commences. Drew steeped inSB knowledge thru long experience at the #1institution in the world—MDA PLUS at Rosenberg’s elbow at the NCI where he led 3 major initiatives. Huge vote of confidence in ziop. #3–EXPERIENCE with 2 prior SB iterations and many patients in CAR-T provides a “DIRECT line of sight for TCR-T” as per elite,HANDS ON KOL Cooper.—(-Go right ahead and Short it and him if you doubt him AND Deniger) #4–Exclusive NCI license for applicable patents and inventions conferred on Ziop for NCI’slibrary of TCR’s reactive to hot spot mutations—P53-KRAS-RAS-EGFR for use with the SB platform AND NCI IP covering diagnostic and manufacturing processes. Bear in mind NCI has CLINICAL grade TCell technology That’s just the solid tumor piece that is in place as the trial commences. JHuang embarked on the POC CD19 JV AFTER the FDA halt. IL12 GBM mono showing overenrollment with elite NON ZIOP investigators interested in expanding the combos. MDA credit enough for all CD19 development well into 2020 and warrant exercises would provide $62 million more.. No shock ziop outperforming ALL those other names presented here over and over as competitors IMO. Meanwhile the outperformer(up 3.5 TIMES) has DEAD silence on its board from the sorry crew who posted many thousands of sneerring gibes on an 80% drawdown. Cat got their tongues? LOL. Risk vs reward ?and NONE of those misfits identifying a risk off PANIC as a reason it bottomed as low as it did. |
return to message board, top of board |